SOURCE: BDI Pharma, Inc.

BDI Pharma, Inc.

September 28, 2009 08:00 ET

Inaugural Season a Success for BDI Pharma's SecuriFLU

COLUMBIA, SC--(Marketwire - September 28, 2009) - BDI Pharma, Inc. (BDI), the fastest growing national wholesale distributor of biotech therapies, announced today the success of its proprietary supply program SecuriFLU. The program provides ordering solutions for customers who require quick, easy access to online ordering for flu vaccine. Customers may access brands from multiple manufacturers offering a full range of age indications. The site is designed to reduce the amount of time spent placing orders and provide a user-controlled ordering process. Customers are able to place orders for immediate delivery, pre-book for the following season and/or select from a customized list of delivery dates to fit their clinics' needs.

The SecuriFLU Program also serves as a clinical resource for consumers and healthcare providers alike. Data on influenza strains, along with CDC's guidelines and recommendations for influenza planning for the existing and upcoming seasons, are made available.

"We recognize not only the importance of making flu vaccine readily accessible, but also the greater value of offering supply and clinical solutions to our customers, especially with the heightened awareness this season due to concerns over the H1N1 (swine flu) pandemic," said Jennifer Jacobson, V.P., Corporate Programs for BDI. "The fact that we were able to ship 100% of our 2009-2010 pre-booked orders, as well as provide a limited number of additional doses to the community, effectively demonstrates that SecuriFLU reached its target audience in its inaugural year."

About BDI Pharma, Inc.

Serving the healthcare community since 1995, BDI Pharma, Inc. has built an outstanding reputation as an industry source for products and service. BDI Pharma's market focus is evident in its commitment to specialty biotherapeutics, chemotherapies, immunologics and hemostatics, including Albumin (Human) USP, intravenous immune globulin (IVIG or IGIV), coagulation factors VIII, IX, and VIIa, as well as hyper-immunes, injectables and physician specialty pharmaceuticals. As a manufacturer recognized Authorized Distributor of Record, BDI Pharma, Inc. services the entire country and is fully accredited and insured, fulfilling the licensing requirements in all 50 states.

In an arena where access to pertinent clinical data and updated information on market availability is paramount to patient care, BDI Pharma, Inc. defines its customer-centric approach to serving the nation's healthcare community through innovative inventory management programs, unparalleled customer service, extensive product knowledge, unique promotional services, emergency availability and urgent need delivery. The company serves as a source for reference material and market data, offering healthcare providers the latest information on products, supply and other industry events. BDI Pharma, Inc.'s educational literature and Web site -- www.bdipharma.com -- serve as open-access resources, contributing to the promotion of the biopharmaceutical industry and the education of both the healthcare community and general populace.

Contact Information

  • Contact:
    Brad Davis
    Director of Marketing
    Email Contact
    (800)948-9834